Edition:
United Kingdom

Rocky Swift

Biotech-for-hire PeptiDream charts new path and becomes short target

14 Nov 2019

TOKYO The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target

13 Nov 2019

TOKYO, Nov 13 The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

RPT-Stung by WeWork, SoftBank boss Son charts more cautious IPO course

07 Nov 2019

TOKYO, Nov 7 Fresh from the WeWork debacle, SoftBank CEO Masayoshi Son says he now aims to be more cautious about the timings of IPOs, a shift that could squeeze the Japanese company's funding and increase its reliance on its lower-growth telecom business.

Stung by WeWork, SoftBank boss Son charts more cautious IPO course

07 Nov 2019

TOKYO Fresh from the WeWork debacle, SoftBank CEO Masayoshi Son says he now aims to be more cautious about the timings of IPOs, a shift that could squeeze the Japanese company's funding and increase its reliance on its lower-growth telecom business.

Stung by WeWork, SoftBank boss Son charts more cautious IPO course

07 Nov 2019

TOKYO, Nov 7 Fresh from the WeWork debacle, SoftBank CEO Masayoshi Son says he now aims to be more cautious about the timings of IPOs, a shift that could squeeze the Japanese company's funding and increase its reliance on its lower-growth telecom business.

Factbox: SoftBank's ever-growing mountain of debt

07 Nov 2019

TOKYO SoftBank Group Corp has built a global conglomerate of telecoms and tech companies on an ever-growing mountain of debt that major rating agencies categorize as junk.

Stada buys Takeda drug bundle to boost Russia business

05 Nov 2019

Germany's Stada on Tuesday agreed to purchase over-the-counter and prescription drugs units from Japan's largest drugmaker Takeda for $660 million (£512 million), part of two deals that boost its Russian and Eastern European footprint.

Factbox: SoftBank's ever-growing mountain of debt

05 Nov 2019

TOKYO SoftBank Group Corp has built a global conglomerate of telecoms and tech companies on an ever-growing mountain of debt that major rating agencies categorize as junk.

Factbox: SoftBank's ever-growing mountain of debt

05 Nov 2019

TOKYO SoftBank Group Corp has built a global conglomerate of telecoms and tech companies on an ever-growing mountain of debt that major rating agencies categorise as junk.

SoftBank to write down minimum $5 billion for WeWork, other losses - Bloomberg

25 Oct 2019

TOKYO SoftBank has ample funds to endure the pain from its massive bailout of WeWork, analysts said, even as it is reportedly set to write down at least $5 billion (£3.9 billion) due to a slump in the value of the U.S. office sharing startup and some other top holdings.

World News